BD announced the commercial launch of its CentroVena One™ Insertion System on April 29, 2026. The device consolidates the introducer needle, syringe, guidewire, and catheter into a single platform, cutting procedural steps by 30 % and insertion time by 50 % according to a December 2025 simulation study.
The system received FDA 510(k) clearance and was accepted into the FDA Safer Technologies Program (STeP), underscoring its safety innovations. A pilot program at UNC Health Blue Ridge demonstrated a streamlined workflow, lower contamination risk, and fewer complications such as pneumothorax and needlestick injuries.
BD’s entry into the acute CVC market taps into a projected $5.86 billion market by 2035, growing at a CAGR of 6.6 % from 2025. The first all‑in‑one system positions BD against competitors like Medtronic and B. Braun, offering a unique safety‑focused solution that could capture a share of the expanding central line market.
Management highlighted the strategic importance of the launch. Ron Silverman, Executive Vice President and Chief Medical Officer, said the system represents “the most meaningful advancement in central line insertion since the technique was first introduced nearly seven decades ago.” He added that reducing procedural steps and protecting against complications supports safer, faster care when every second counts.
BD’s Q1 fiscal 2026 results showed revenue of $5.3 billion, a 0.4 % increase on a currency‑neutral basis, and adjusted diluted EPS of $2.91. The company’s focus on new product launches like CentroVena One™ signals a shift toward high‑margin, innovation‑driven growth, complementing its broader “New BD” transformation.
The launch is expected to strengthen BD’s vascular access portfolio and could drive future revenue growth in the acute CVC segment, though the company has not yet provided specific sales targets for the new system.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.